Related Experiment Videos
The dilemma of mild hyperprolactinaemia
Summary
Bromocriptine treatment effectively helps women with mild hyperprolactinaemia achieve pregnancy and resolve symptoms. Some patients experience spontaneous resolution of hyperprolactinaemia and fertility after stopping bromocriptine therapy.
Area of Science:
- Endocrinology
- Reproductive Medicine
- Oncology
Background:
- Mild hyperprolactinaemia affects reproductive function and can be associated with pituitary tumours.
- Long-term outcomes and management strategies for mild hyperprolactinaemia require further investigation.
Purpose of the Study:
- To evaluate the efficacy and safety of bromocriptine therapy in women with mild hyperprolactinaemia.
- To assess the impact of bromocriptine on fertility, spontaneous resolution, and pituitary tumour progression.
Main Methods:
- A prospective follow-up study of 98 women with mild hyperprolactinaemia (less than 4N) over a mean of 5.5 years.
- Treatment involved bromocriptine (+/- clomiphene) for desired pregnancies.
- Pituitary tumours were monitored via coned-view assessment and CAT scans.
Main Results:
- Bromocriptine was effective in achieving pregnancy in 87% of women.
- Nearly one-third of patients experienced spontaneous resolution of hyperprolactinaemia after discontinuing bromocriptine.
- Pituitary tumours were identified in 9% at presentation and 10% during follow-up; none progressed with bromocriptine treatment.
Conclusions:
- Bromocriptine therapy is justified for mild hyperprolactinaemia to manage galactorrhoea, achieve pregnancy, and promote spontaneous resolution.
- Bromocriptine can control pituitary tumour growth and reduce tumour development risk in these patients.